- Healthy (healthy is defined as the absence of clinically-relevant abnormalities
identified by a detailed medical history, full physical examination, 12-lead ECG and
clinical laboratory tests).
- Free of any medical or surgical conditions that might significantly interfere with
gastrointestinal absorption, distribution, metabolism, or excretion of Dimebon.
- Demographically comparable to subjects with mild and moderate hepatic impairment.
- Subjects with hepatic impairment: Screening medical history, physical examination,
vital signs, 12-lead ECG, and clinical laboratory tests performed within 28 days
before the first dose of study medication, abnormal findings that are related to the
subject's underlying condition are acceptable.
- Satisfy the criteria for Class A, B, or C of the modified Child-Pugh classification
[Mild (Child-Pugh Scores 5-6 points), moderate (Child-Pugh Scores 7-9 points), and
severe (Child-Pugh Scores >9 and
study medication.
- A diagnosis of hepatic impairment due to cirrhosis, not secondary to other diseases,
which is confirmed and documented by medical history, physical examination, liver
biopsy or hepatic ultrasound, CT scan or MRI.
- Subjects presenting with any of the following will not be included in the trial:CYP2D6
PM genotype, as identified by screening genotyping.
- A known sensitivity to Dimebon.
- Exposure within the previous three months to a drug known to have a negative effect on
skeletal muscle or reproductive organs.
- History of febrile illness within 5 days prior to the first dose.
- Any condition possibly affecting drug absorption (e.g., gastrectomy, active peptic
ulcer within last 3 months).